CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03389802
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:23.278764+00:00
Published At: 2024-10-10T00:00:00+00:00
Record Updated At: 2026-02-20
Results Posted At: 2024-10-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Glioblastoma Multiforme", "High-grade Astrocytoma Not Otherwise Specified (NOS)", "CNS Primary Tumor, Not Otherwise Specified (NOS)", "Ependymoma, Not Otherwise Specified (NOS)", "Diffuse Intrinsic Pontine Gliomas (DIPG)", "Medulloblastoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-20"
protocolSection.identificationModule.nctId: "NCT03389802"
protocolSection.identificationModule.officialTitle: "Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-10-10"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.